Speakers for this year's event include:
Ron Gladue, Research Fellow, Pfizer
Lynn Miesel, Senior Research Fellow, Merck
Neil Ryder, Executive Director, Microbial Vaccines, Novartis
Chris Longshaw, Associate Director of Microbiology, Astellas
Sheo Singh, Senior Investigator, Merck
Mick Gwynn, Director, Microbiology & Infectious Diseases, GlaxoSAE Media GroupthKline
Markus Heep, Principal Medical Scientific Expert, Novartis
Amita Joshi, Sr Research Immunologist, Microbial Vaccines, Merck
Justin Montgomery, Senior Principal Scientist, Pfizer
Bret Sellman, Principal Scientist, Medimmune
Richard Bax, Senior Partner, Transcrip Partners
Christian Felter, Associate Director, Medical Affairs, Astellas
Alice Erwin, Research Fellow, Antibacterial Drug Discovery, Vertex Pharmaceuticals
Conference agenda
Welcome and Introductions Overview: The rate limiting steps in antibacterial discovery Permeability barriers and efflux: getting through or around? Chemical sources: Improving libraries and reviving natural products The right targets: will single enzyme targets fly? Welcome and Introductions Medical need and worldwide drug development activities Changing environment of antibacterial drug R&D International actions in Europe & US - Activites outside the industry Implications for R&D and partnering - new models of R&D Chairman's Opening Remarks Richard Bax, Senior Partner, TranScrip Partners Anti-bacterials; past, present and future Richard Bax, Senior Partner, TranScrip Partners
Past success stories and how to learn from them
The current state of developments in anti-bacterial advances
Where industry are standing, and future plans for anti-bacterial development
Predicting obstacles and plans to overcome them
Multidrug Resistant Bacteria- Where do we stand? Neil Woodford, Acting Director, Health Protection Agency
MDR Bacteria related to hospital infections
Detecting resistance earlier, and strategies to counter resistance
Recent success stories/failures and what can we learn from past experiences
Generation of new antibacterial lead molecules: an approach to develop combination therapies for MRSA infections Lynn Miesel, Biology Collaboration Lead, Merck Research Laboratories
Whole cell screen to identify b-lactam synergists
Methods to define the cellular target of novel antibacterials
New b-lactam synergy targets
Advances in development of AFN-1252, a specific-spectrum, anti-staphylococcal agent Barry Hafkin, CMO, Affinium Pharmaceuticals
Review the novel mechanism of action for this new class of drugs, and provide recent in vitro date validating the FabI target for Staphylococcus spp.
Present recent in vitro, in vivo animal and human clinical data supporting the progression of AFN-1252 into Phase 2 trials
Discuss the potential role for a new anti-Staphyloccocal agent in medical practice
Targeting Multidrug Resistant Bugs: The Pivotal Role of Preclinical Efficacy Models in Drug Discovery
Overview of preclinical models for efficacy determination.
Emerging resistance and novel approaches to efficacy modelling.
Preclinical PKPD modelling as an aid to design of clinical trials
Lloyd Payne, Chief Executive Officer, Euprotec Peter Warn, Director, Euprotec Chemical genetic profiling and discovery of Kibdelomycin, a potent new class of bacterial Type II Topoisomerase Inhibitor Sheo Singh, Distinguished Senior Investigator, Merck Research Lab
Chemical genetic profiling of natural products accelerates antibiotic discovery
Identification of a new class of antibiotics from a new member of Kibdelosporangium
Kibdelomycin exhibits broad spectrum gram positive antibacterial activity
Kibdelomycin is a potent inhibitor of bacterial type-II topoisomerases
Safe drugs for bad bugs – EV-035, a new topoisomerase inhibitor Jutta Heim, Professor of Biotechnology, Chief Scientific Officer, Evolva SA • Novel 2-pyridones
• Broad-spectrum and very potent
• Active on MDR pathogens, including quinolone resistance
• Favourable PK and Tox profile
• Active in in vivo models Antibacterial developments in Tuberculosis research Anthony Coates, Professor, St George Hospital Medical School
New models are needed for anti-bacterial development in TB
Novel in vitro models which mimic TB persister bacteria
Considering a new murine model which is more similar to human tuberculosis than current models
Tuberculosis treatment failure: bad bugs of bad drugs? Guy Thwaites, Visiting Research, Imperial College London
When does TB treatment fail?
Do M. Tuberculosis ‘superbugs’ exist?
Does bacterial genetic variation influence disease phenotype and response to treatment?
Or are our drugs inadequate?
Assessing the FDA's Objective Endpoints and Clinical Test of Cure: Results from a Phase 2B ABSSSI Study Comparing Delafloxacin with Vancomycin and Zyvox Jarrod Longcor, Director Business Development, Rib-X Pharmaceuticals
Delafloxacin is a unique fluoroquinolone, with broad-spectrum activity, including MRSA, demonstration of efficacy in 4 Phase 2 clinical trials and a strong safety profile in nearly 1400 patients
Delafloxacin shows a statistically significant difference in rates of efficacy in the Phase 2B trial when compared with vancomycin
Delafloxacin shows not only lesion-spread cessation in the 48 - 72 hour window but also substantial lesion reduction in the same timeframe
Delafloxacin is efficacious across lesion types, including major abscesses, cellulitis, wounds and burns, in a population with mean and median lesion sizes larger than seen in historical trials
Novel antibacterial development for multidrug resistant bugs Chris Longshaw, Associate Director, Microbiology, Astellas Pharma Europe
Current treatment options for Clostridium difficile infection
Fidaxomicin: a new treatment paradigm?
An overview of other CDI therapies in development
Multi-resistant bacteria case study: C. Diff Christian Felter, Associate Director, Medical Affairs, Astellas Pharma Europe
The spectrum of C. Diff infections and their effects on patients
Guidelines outlined by the HICPAC
How and why transmissions occur in healthcare facilities
Chairman’s Closing Remarks and Close of Day One Chairman's Opening Remarks Ronald Gladue, Research Fellow, Pfizer Global Biotherapeutics Technologies Development of vaccines for the prevention of antibiotic-resistant bacterial infections Amita Joshi, Sr Research Immunologist, Merck Research Laboratories
Focus on Staphylococcus aureus
Identifying vaccine targets through rational design
Preclinical data: towards a changing paradigm for protection
Fungal Infection; trends and progress in novel therapies Neil Ryder, Executive Director, Infectious Diseases, Novartis Institutes for Biomedical Research Inc.
Emerging fungal pathogens and the need for new drugs
Trends in antifungal drug resistance
Recent developments in novel antifungal therapies
Targeted approached: do they (can they) work?
Antibody based therapies for the treatment and prevention of bacterial infections Ronald Gladue, Research Fellow, Pfizer Global Biotherapeutics Technologies
Rationale and desired characteristics
Strategy and preclinical date
Focus on gram negative infections
Exploiting Novel Bacterial Topoisomerase Inhibitors (NBTIs) with public-private partnerships Michael Gwynn, Director, Microbiology, Infectious Diseases CEDD, GlaxoSmithKline • Brief pipeline review
• Structure based exploitation of DNA gyrase
• Importance of public-private partnerships Can target-based projects discover novel gram-negative antibiotics? LpxX as an example Alice Erwin, Research Fellow, Antibacterial Drug Discovery, Vertex Pharmaceuticals Inc
Critical issues in discovery of novel classes of Gram-negative antibiotics
History of LpxC as a target illustrates the successes and the problems
Cell-based pathway screen led to first generation of LpxC inhibitors (Merck)
Later projects: broader spectrum and efficacy in animals
No clinical candidates - yet
Novel LpxC inhibitors for treatment of gram-negative infections Justin Montgomery, Senior Principal Scientist, Pfizer Antibacterials RU
The SAR of a new series of LpxC inhibitors
PK and strategies to lower human dose projections
X-ray crystallographic analysis of bound inhibitors
MIC90s for multiple Gram-Negatives
Modifications of beta-lactams to meet the challenge of bacterial resistance Malcolm Page, Head of Biology, Basilea Pharmaceutica Ltd
Beta-lactam resistance in Gram-positive and Gram-Negative bacteria
Anti-MRSA cephalosporins
Siderophore beta-lactams - circumventing the Gram-Negative permeability barrier
Engineering beta-lactamase stability in cephems
The antibiotic pipeline: where is it and what needs fixing? Barry I Eisenstein, Senior VP, Scientific Affairs, Cubist Pharmaceuticals
The unique public health threat posed by growing bacterial resistance to antibiotics
The present challenges of the R&D investment model for antibacterials
The associated public policy imperatives
Potential government-driven solutions to fix this 'market failure'
Discussion into the current work carried out by the PhRMA committee on emerging pathogens
‘Almost there?’ – The challenges of late-phase antibiotic development Markus Heep, Principal Medical Scientific Expert, Novartis Pharma GmbH
Focus on the most frequent phase III indications
Systemic treatment of gram-positive or mixed infections
Skin infections and Pneumonia
The EU research strategy to combat antimicrobial resistance Line Matthiessen, Head of Infectious Diseases and Public Health Unit, European Commision
Review of the Commission's action plan against the rising threats from antimicrobial resistance
Discussion into the effects of the plan, launched November 2011
Evaluating current and future research activites
Antibacterial developments in South East Asia Stephen Baker, Microbiologist, Oxford University Clinical Research Unit
Antibacterials in emerging markets
The role of public funding in anti-infective research and development
Research and development tax incentives
Chairman’s Closing Remarks and Close of Day Two
Workshops
Copthorne Tara Hotel 7 March 2012 London, United Kingdom Copthorne Tara Hotel 7 March 2012 London, United Kingdom
copyright ©
2024
SAE Media Group
|